An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant is treated with bevacizumab at the end of the Roche/Genentech sponsored parent trial and continues to have benefit as judged by the investigator
Eligible for continuation of bevacizumab treatment at the end of a parent trial, according to parent trial protocol
Able to comply with this extension study protocol (MO25757)
You may not be if
Evidence of disease progression assessed according to parent trial protocol during the screening phase for this extension study
Evidence of any adverse event potentially attributable to bevacizumab, for which the local label recommends permanent discontinuation
A treatment interruption with bevacizumab of more than 42 days since the last administration of bevacizumab in the parent trial
Evidence of any other disease that would put the participant at high risk for treatment-related complications
Clareo Health | An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study
